, Tracking Stock Market Picks
Enter Symbol:
Rating: MDVN
Buy $74

MEDIVATION INC (NASDAQ: MDVN) reiterated to Buy with price target $74 by Maxim Group

Monday,  Sep 28, 2015  8:25 AM ET by Lynn Gilbert

Maxim Group reiterated MEDIVATION INC (NASDAQ: MDVN) to Buy with price target
$74. Previously, Maxim Group rated MEDIVATION INC (NASDAQ: MDVN) to Buy with price target $163 on 03/30/2015, when the stock price was valued at $134.79.

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three medical needs: Alzheimer?s disease, Huntington?s disease and castration-resistant prostate cancer. The Company has formed separate subsidiaries to hold the product candidates it is developing. The Company?s subsidiary Medivation Neurology, Inc. holds its Dimebon technology, and its subsidiary Medivation Prostate Therapeutics, Inc. holds its MDV300 series technology.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy